Benefits seen for oxidative stress markers, inflammatory indices, and liver enzymes
FRIDAY, Jan. 31, 2025 (HealthDay News) — Intermittent fasting may benefit antioxidant and inflammatory markers in postmenopausal women with rheumatoid arthritis, according to a study published online Jan. 18 in Scientific Reports.
Aryan Tavakoli, from the School of Nutritional Sciences and Dietetics at the Tehran University of Medical Sciences in Iran, and colleagues randomly assigned 44 postmenopausal women (with overweight or obesity) with rheumatoid arthritis to either following a 16:8 intermittent fasting diet or their usual diet.
The researchers found that the intermittent fasting group showed significant decreases in serum malondialdehyde levels and neutrophil-to-lymphocyte ratio and increased catalase levels versus the control group. There were also significant decreases seen in the liver enzymes aspartate transaminase and alanine transaminase in the intermittent fasting group.
“In conclusion, these findings indicate that intermittent fasting may offer a valuable nonpharmacological approach to managing rheumatoid arthritis in this specific population, addressing both the primary disease symptoms and associated metabolic complications,” the authors write. “While further research is needed to fully elucidate the mechanisms and long-term effects, this study provides strong evidence for the potential of intermittent fasting as an adjunct therapy in the management of rheumatoid arthritis, particularly in postmenopausal women who are overweight and obese.”
Estimated Glucose Disposal Rate Inversely Linked to Benign Prostatic Hyperplasia
Small Change in Hours Benefits Emergency Physicians Working Night Shifts
Safety Intervention Reduces Incidence of Postoperative Endophthalmitis
Menopausal Hormone Therapy Use Linked to Lower Risk for Alzheimer Disease
Cortical Atrophy in Early-Onset Alzheimer Disease Signature Can Predict Progression to Dementia
Exercise Link to Dementia Varies by Physical Activity Domain
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy